Artelo Biosciences, Inc.
A complete Wall Street Score is unavailable because required model components are missing. Missing model components: revenue, moat, financial, Buffett-style model component. These are scoring components, not a claim that the company has no assets or earnings. Missing inputs are not zero and do not by themselves make this a weak company. Available financial statements and source-backed research remain visible.
ARTL · Price history
Price at last available close
$2.31
−$1.73 (-42.82%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Artelo Biosciences, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27. 13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.
How they make money
Artelo Biosciences is a clinical-stage pharmaceutical company that generates no revenue from product sales. Its business model relies on raising capital through equity and debt offerings to fund the research, development, and potential future commercialization of proprietary therapeutics that modulate lipid-signaling pathways.
Products & services
The company is developing a portfolio of product candidates including ART26.12 (a Fatty Acid Binding Protein inhibitor), ART27.13 (a dual cannabinoid receptor agonist), and ART12.11 (a synthetic cannabidiol analog) for conditions such as cancer, pain, and dermatologic disorders.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Patients with cancer, pain, dermatologic, or neurological conditionsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company utilizes various third-party contract research organizations to conduct clinical trials and preclinical studies; specific supplier names are not disclosed.Source
Strengths
- Proprietary portfolio of lipid-signaling pathway modulatorsSource
Sources
Company-specific research
Questions worth answering for ARTL
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can ARTL fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is ARTL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for ARTL to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ARTL's current valuation?
- •What does the current corporate distress warning mean for the reliability or interpretation of ARTL's score?
Essential Investment Snapshot
Market Cap
$8.1M
P/E Ratio
-0.1
EPS
$-74.28
52-Week High
$179.19
52-Week Low
$3.45
Beta
-0.07
Shares Outstanding
262K
Total Debt
$49K
Dividend
No current dividend
Liquidation Value / Share
$19.08
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ARTL
Detected from reported data — verify before acting.MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCRITICAL: Going-concern warning
A recent SEC filing contains explicit going-concern language. Wall Street Score is capped at 15 until the distress condition is resolved in later filings.
Supporting filingDebt service risk
Interest coverage is low (~-58.8x). Earnings may be strained to cover interest expense.
Reverse-split headline · Aug 27, 2026
Artelo Biosciences Announces Reverse Stock Split — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on ARTL.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary portfolio of lipid-signaling pathway modulators.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and dependence on future financing.
- −Clinical trial failure and regulatory approval uncertainty.
- −A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$2.31
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $3.8M | $5.4M | $6.0M | $5.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $7.3M | $6.0M | $4.1M | $4.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $11.1M | $11.4M | $10.1M | $9.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$12.1M | -$12.5M | -$9.8M | -$9.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$11.1M | -$11.4M | -$10.1M | -$9.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $618K | $194K | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$12.7M | -$12.9M | -$9.8M | -$9.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$12.7M | -$12.9M | -$9.8M | -$9.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-74.28 | $-49.23 | $-9.15 | $-9.42 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 301K | 262K | 1.07M | 987K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 301K | 262K | 1.07M | 987K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$8.01
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-94.4%
Cash Change
+103.2%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included cash levels, debt levels. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 52.4%. Cash increased 103.2%. Total debt declined 94.4%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Artelo Biosciences, Inc. (NASDAQ:ARTL) Stock Short Interest Rises 104.7%
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
Rumor Mill · ARTL
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial